New study checks if IBD drug skyrizi seeps into breast milk

NCT ID NCT06346288

Completed Knowledge-focused Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how much of the drug risankizumab (Skyrizi) passes into the breast milk of women with inflammatory bowel disease (IBD). Ten breastfeeding mothers who were already taking the drug provided milk samples over several weeks. The goal is to understand potential exposure to nursing infants and help guide safe breastfeeding recommendations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: risankizumab (Skyrizi)
What this could lead to: If successful, this study could provide data to help doctors and mothers make informed decisions about breastfeeding while on risankizumab.
What could go wrong: This is a small, observational study with only 10 participants. It measures drug levels in milk but does not directly test infant safety or long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Breast Feeding Crohn disease inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLAMMATORY BOWEL DISEASE

Contacts and locations

Locations

Shaare Zedek Medical Center /ID# 262738

Jerusalem, Jerusalem, 91031, Israel
UTHealth Women's Research Program - Memorial City /ID# 263939

Houston, Texas, 77024, United States
University of North Carolina at Chapel Hill /ID# 263316

Chapel Hill, North Carolina, 27514, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.